Additionally, GLP-1 receptor agonist users experienced fewer arrhythmic events, a lower rate of hospitalization for HF worsening, and a higher probability of the patient responding to cardiac resynchronization therapy with a defibrillator in the follow-up period (29). Here, GLP1R is linked to hydrops fetalis.